KDM4B as a target for prostate cancer

Structural analysis and selective inhibition by a novel inhibitor

Chia Han Chu, Ling Yu Wang, Kai Cheng Hsu, Chung Chin Chen, Hsing Hung Cheng, Szu Min Wang, Chien Ming Wu, Tsan Jan Chen, Ling Ting Li, Ruiwu Liu, Chiu Lien Hung, Jing Moon Yang, Hsing-Jien Kung, Wen Ching Wang

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The KDM4/JMJD2 Jumonji C-containing histone lysine demethylases (KDM4A-KDM4D), which selectively remove the methyl group(s) from tri/dimethylated lysine 9/36 of H3, modulate transcriptional activation and genome stability. The overexpression of KDM4A/KDM4B in prostate cancer and their association with androgen receptor suggest that KDM4A/KDM4B are potential progression factors for prostate cancer. Here, we report the crystal structure of the KDM4B·pyridine 2,4-dicarboxylic acid·H3K9me3 ternary complex, revealing the core active-site region and a selective K9/K36 site. A selective KDM4A/KDM4B inhibitor, 4, that occupies three subsites in the binding pocket is identified by virtual screening. Pharmacological and genetic inhibition of KDM4A/KDM4B significantly blocks the viability of cultured prostate cancer cells, which is accompanied by increased H3K9me3 staining and transcriptional silencing of growth-related genes. Significantly, a substantial portion of differentially expressed genes are AR-responsive, consistent with the roles of KDM4s as critical AR activators. Our results point to KDM4 as a useful therapeutic target and identify a new inhibitor scaffold.

Original languageEnglish (US)
Pages (from-to)5975-5985
Number of pages11
JournalJournal of Medicinal Chemistry
Volume57
Issue number14
DOIs
StatePublished - Jul 24 2014

Fingerprint

Prostatic Neoplasms
Histone Demethylases
Genomic Instability
Androgen Receptors
Transcriptional Activation
Genes
Lysine
Catalytic Domain
Pharmacology
Staining and Labeling
Growth
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Chu, C. H., Wang, L. Y., Hsu, K. C., Chen, C. C., Cheng, H. H., Wang, S. M., ... Wang, W. C. (2014). KDM4B as a target for prostate cancer: Structural analysis and selective inhibition by a novel inhibitor. Journal of Medicinal Chemistry, 57(14), 5975-5985. https://doi.org/10.1021/jm500249n

KDM4B as a target for prostate cancer : Structural analysis and selective inhibition by a novel inhibitor. / Chu, Chia Han; Wang, Ling Yu; Hsu, Kai Cheng; Chen, Chung Chin; Cheng, Hsing Hung; Wang, Szu Min; Wu, Chien Ming; Chen, Tsan Jan; Li, Ling Ting; Liu, Ruiwu; Hung, Chiu Lien; Yang, Jing Moon; Kung, Hsing-Jien; Wang, Wen Ching.

In: Journal of Medicinal Chemistry, Vol. 57, No. 14, 24.07.2014, p. 5975-5985.

Research output: Contribution to journalArticle

Chu, CH, Wang, LY, Hsu, KC, Chen, CC, Cheng, HH, Wang, SM, Wu, CM, Chen, TJ, Li, LT, Liu, R, Hung, CL, Yang, JM, Kung, H-J & Wang, WC 2014, 'KDM4B as a target for prostate cancer: Structural analysis and selective inhibition by a novel inhibitor', Journal of Medicinal Chemistry, vol. 57, no. 14, pp. 5975-5985. https://doi.org/10.1021/jm500249n
Chu, Chia Han ; Wang, Ling Yu ; Hsu, Kai Cheng ; Chen, Chung Chin ; Cheng, Hsing Hung ; Wang, Szu Min ; Wu, Chien Ming ; Chen, Tsan Jan ; Li, Ling Ting ; Liu, Ruiwu ; Hung, Chiu Lien ; Yang, Jing Moon ; Kung, Hsing-Jien ; Wang, Wen Ching. / KDM4B as a target for prostate cancer : Structural analysis and selective inhibition by a novel inhibitor. In: Journal of Medicinal Chemistry. 2014 ; Vol. 57, No. 14. pp. 5975-5985.
@article{af89268ece7e4ce087ccb5ba82905b6e,
title = "KDM4B as a target for prostate cancer: Structural analysis and selective inhibition by a novel inhibitor",
abstract = "The KDM4/JMJD2 Jumonji C-containing histone lysine demethylases (KDM4A-KDM4D), which selectively remove the methyl group(s) from tri/dimethylated lysine 9/36 of H3, modulate transcriptional activation and genome stability. The overexpression of KDM4A/KDM4B in prostate cancer and their association with androgen receptor suggest that KDM4A/KDM4B are potential progression factors for prostate cancer. Here, we report the crystal structure of the KDM4B·pyridine 2,4-dicarboxylic acid·H3K9me3 ternary complex, revealing the core active-site region and a selective K9/K36 site. A selective KDM4A/KDM4B inhibitor, 4, that occupies three subsites in the binding pocket is identified by virtual screening. Pharmacological and genetic inhibition of KDM4A/KDM4B significantly blocks the viability of cultured prostate cancer cells, which is accompanied by increased H3K9me3 staining and transcriptional silencing of growth-related genes. Significantly, a substantial portion of differentially expressed genes are AR-responsive, consistent with the roles of KDM4s as critical AR activators. Our results point to KDM4 as a useful therapeutic target and identify a new inhibitor scaffold.",
author = "Chu, {Chia Han} and Wang, {Ling Yu} and Hsu, {Kai Cheng} and Chen, {Chung Chin} and Cheng, {Hsing Hung} and Wang, {Szu Min} and Wu, {Chien Ming} and Chen, {Tsan Jan} and Li, {Ling Ting} and Ruiwu Liu and Hung, {Chiu Lien} and Yang, {Jing Moon} and Hsing-Jien Kung and Wang, {Wen Ching}",
year = "2014",
month = "7",
day = "24",
doi = "10.1021/jm500249n",
language = "English (US)",
volume = "57",
pages = "5975--5985",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "14",

}

TY - JOUR

T1 - KDM4B as a target for prostate cancer

T2 - Structural analysis and selective inhibition by a novel inhibitor

AU - Chu, Chia Han

AU - Wang, Ling Yu

AU - Hsu, Kai Cheng

AU - Chen, Chung Chin

AU - Cheng, Hsing Hung

AU - Wang, Szu Min

AU - Wu, Chien Ming

AU - Chen, Tsan Jan

AU - Li, Ling Ting

AU - Liu, Ruiwu

AU - Hung, Chiu Lien

AU - Yang, Jing Moon

AU - Kung, Hsing-Jien

AU - Wang, Wen Ching

PY - 2014/7/24

Y1 - 2014/7/24

N2 - The KDM4/JMJD2 Jumonji C-containing histone lysine demethylases (KDM4A-KDM4D), which selectively remove the methyl group(s) from tri/dimethylated lysine 9/36 of H3, modulate transcriptional activation and genome stability. The overexpression of KDM4A/KDM4B in prostate cancer and their association with androgen receptor suggest that KDM4A/KDM4B are potential progression factors for prostate cancer. Here, we report the crystal structure of the KDM4B·pyridine 2,4-dicarboxylic acid·H3K9me3 ternary complex, revealing the core active-site region and a selective K9/K36 site. A selective KDM4A/KDM4B inhibitor, 4, that occupies three subsites in the binding pocket is identified by virtual screening. Pharmacological and genetic inhibition of KDM4A/KDM4B significantly blocks the viability of cultured prostate cancer cells, which is accompanied by increased H3K9me3 staining and transcriptional silencing of growth-related genes. Significantly, a substantial portion of differentially expressed genes are AR-responsive, consistent with the roles of KDM4s as critical AR activators. Our results point to KDM4 as a useful therapeutic target and identify a new inhibitor scaffold.

AB - The KDM4/JMJD2 Jumonji C-containing histone lysine demethylases (KDM4A-KDM4D), which selectively remove the methyl group(s) from tri/dimethylated lysine 9/36 of H3, modulate transcriptional activation and genome stability. The overexpression of KDM4A/KDM4B in prostate cancer and their association with androgen receptor suggest that KDM4A/KDM4B are potential progression factors for prostate cancer. Here, we report the crystal structure of the KDM4B·pyridine 2,4-dicarboxylic acid·H3K9me3 ternary complex, revealing the core active-site region and a selective K9/K36 site. A selective KDM4A/KDM4B inhibitor, 4, that occupies three subsites in the binding pocket is identified by virtual screening. Pharmacological and genetic inhibition of KDM4A/KDM4B significantly blocks the viability of cultured prostate cancer cells, which is accompanied by increased H3K9me3 staining and transcriptional silencing of growth-related genes. Significantly, a substantial portion of differentially expressed genes are AR-responsive, consistent with the roles of KDM4s as critical AR activators. Our results point to KDM4 as a useful therapeutic target and identify a new inhibitor scaffold.

UR - http://www.scopus.com/inward/record.url?scp=84905039523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905039523&partnerID=8YFLogxK

U2 - 10.1021/jm500249n

DO - 10.1021/jm500249n

M3 - Article

VL - 57

SP - 5975

EP - 5985

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 14

ER -